Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis股票下跌，因公司宣佈歐盟CHMP對使用眼內注射Pegcetacoplan治療地理萎縮症的市場授權申請做出負面意見。
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis股票下跌，因公司宣佈歐盟CHMP對使用眼內注射Pegcetacoplan治療地理萎縮症的市場授權申請做出負面意見。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。